The company's research is focused on the use of the oncofetal antigen ("OFA"), or more specifically, iLRP - immature Laminin Receptor Protein, as a cancer immunogen
(a cancer target against which the immune system is directed) found in many tumor cell lines or fetal tissue, but not found in normal mature tissue.
EpiCor, the immune balancing, all-natural, high-metabolite immunogen
manufactured by Embria Health Sciences, was recently the subject of a June 2007 Nutrition Research Journal in vitro study that evaluated the consumable ingredient's immunomodulating effects on human leukocytes.
(Malvern, Pennsylvania/USA), California/USA), GPC Biotech AG (Munich/Germany), Hoffmann- La Roche AG (Basel/Switzerland), ImmunoGen
Recent findings by Aphton Corporation, Miami, and its collaborating scientists, working with Aphton's anti-gastrin immunogen
and anti-gastrin receptor antibodies, indicate that gastrin receptors are expressed in abundance in the respiratory system.
(4), a proposed rare and new species of rapidly growing mycobacteria with similarities to both M.
completed an in-depth operational review based on which the company will prioritize continued development of mirvetuximab and a select portfolio of three earlier-stage product candidates targeting solid tumors and hematological malignancies.
In 2015, ImmunoGen
announced a USD 200m non-dilutive royalty transaction through which ImmunoGen
sold the right to receive 100% of the royalty revenue on Kadcyla commercial sales to an undisclosed threshold amount, subject to certain conditions.
The product is an antibody drug conjugate that includes a fully human antibody targeting CD205, coupled to the DM4 toxin from Immunogen
. It is being developed for a number of CD205 driven tumours including Her2 negative breast cancer, gastric cancer, triple-negative metastatic breast cancer, bladder cancer, pancreatic cancers and Non-Hodgkin Lymphoma.
and Merck have entered into a clinical research collaboration to assess ImmunoGen
's mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), for the treatment of patients with FR-alphapositive ovarian cancer.
competition assay (ICA) is a recommended procedure for confirming the epitope-specific binding activity of antibodies.
Present study is designed to improve its potency through adjusting optimum level of the virus immunogen
and suitable adjuvant.